| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $118,250 | 1 | 6 |
Sells | $8,678,964 | 15 | 94 |
| Mashal Robert | director | 1 | $118,250 | 0 | $0 | $118,250 |
| Sauvage Philippe | Chief Financial Officer | 0 | $0 | 1 | $286,370 | $-286,370 |
| Markel Stacy | CHIEF PEOPLE OFFICER | 0 | $0 | 1 | $753,188 | $-753,188 |
| Hanley David C. | CHIEF TECHNICAL OPERATIONS | 0 | $0 | 1 | $1.43M | $-1.43M |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | 0 | $0 | 3 | $1.47M | $-1.47M |
| Liu Dongfang | CHIEF MEDICAL OFFICER | 0 | $0 | 7 | $1.87M | $-1.87M |
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 2 | $2.88M | $-2.88M |
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique …
Over the last 12 months, insiders at Nuvation Bio Inc. have bought $118,250 and sold $8.68M worth of Nuvation Bio Inc. stock.
On average, over the past 5 years, insiders at Nuvation Bio Inc. have bought $4.11M and sold $15.01M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Mashal Robert (director) — $118,250.
The last purchase of 25,000 shares for transaction amount of $118,250 was made by Mashal Robert (director) on 2026‑06‑09.
| 2026-08-19 | Sale | Hattersley Gary | CHIEF SCIENTIFIC OFFICER | 100,000 0.0281% | $7.09 | $709,240 | -22.59% | |
| 2026-06-23 | Sale | Wentworth Kerry | CHIEF REGULATORY OFFICER | 63,000 0.0181% | $6.02 | $379,191 | -2.32% | |
| 2026-06-23 | Sale | Markel Stacy | CHIEF PEOPLE OFFICER | 125,000 0.0359% | $6.03 | $753,188 | -2.32% | |
| 2026-06-23 | Sale | Sauvage Philippe | Chief Financial Officer | 47,668 0.0137% | $6.01 | $286,370 | -2.32% | |
| 2026-06-09 | Mashal Robert | director | 25,000 0.0069% | $4.73 | $118,250 | +17.85% | ||
| 2026-04-17 | Sale | Wentworth Kerry | CHIEF REGULATORY OFFICER | 36,750 0.0105% | $5.01 | $184,279 | +10.24% | |
| 2026-04-17 | Sale | Liu Dongfang | CHIEF MEDICAL OFFICER | 50,000 0.0143% | $5.02 | $251,000 | +10.24% | |
| 2026-04-06 | Sale | Wentworth Kerry | CHIEF REGULATORY OFFICER | 200,000 0.0586% | $4.52 | $903,560 | +19.78% | |
| 2025-12-01 | Sale | Liu Dongfang | CHIEF MEDICAL OFFICER | 150,000 0.0435% | $7.82 | $1.17M | -28.68% | |
| 2025-11-26 | Sale | Liu Dongfang | CHIEF MEDICAL OFFICER | 10,000 0.0029% | $8.00 | $80,000 | -29.78% | |
| 2025-11-25 | Sale | Liu Dongfang | CHIEF MEDICAL OFFICER | 10,000 0.0031% | $7.50 | $75,000 | -28.55% | |
| 2025-11-20 | Sale | Liu Dongfang | CHIEF MEDICAL OFFICER | 20,000 0.0058% | $7.00 | $140,074 | -19.54% | |
| 2025-11-20 | Sale | Hattersley Gary | CHIEF SCIENTIFIC OFFICER | 300,000 0.0904% | $7.23 | $2.17M | -19.54% | |
| 2025-11-19 | Sale | Hanley David C. | CHIEF TECHNICAL OPERATIONS | 200,000 0.0584% | $7.14 | $1.43M | -21.12% | |
| 2025-11-19 | Sale | Liu Dongfang | CHIEF MEDICAL OFFICER | 15,000 0.0031% | $5.10 | $76,553 | -21.12% | |
| 2025-11-17 | Sale | Liu Dongfang | CHIEF MEDICAL OFFICER | 15,000 0.0045% | $4.76 | $71,475 | +20.77% | |
| 2025-10-27 | Sale | Hattersley Gary | CHIEF SCIENTIFIC OFFICER | 100,000 0.0334% | $5.02 | $502,460 | +11.31% | |
| 2025-06-18 | Markel Stacy | CHIEF PEOPLE OFFICER | 10,000 0.0028% | $1.71 | $17,100 | +160.89% | ||
| 2025-06-17 | Sauvage Philippe | Chief Financial Officer | 4,000 0.0012% | $1.79 | $7,160 | +171.34% | ||
| 2025-06-16 | Hung David | PRESIDENT AND CEO | 500,000 0.1416% | $1.79 | $893,500 | +148.92% |
| Mashal Robert | director | 225000 0.0643% | $1.06M | 3 | 0 | +56.4% |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | 53000 0.0151% | $248,570.00 | 1 | 3 | +148.92% |
| Markel Stacy | CHIEF PEOPLE OFFICER | 32591 0.0093% | $152,851.79 | 1 | 1 | +160.89% |
| Sauvage Philippe | Chief Financial Officer | 12673 0.0036% | $59,436.37 | 2 | 1 | +160.13% |
| Hung David | PRESIDENT AND CEO | 59281054 16.9315% | $278.03M | 3 | 0 | +125.39% |
| NODELMAN OLEG | director | 12674775 3.6201% | $59.44M | 12 | 2 | +4.57% |
| Cui Xiangmin | director | 2453131 0.7006% | $11.51M | 4 | 0 | <0.0001% |
| EcoR1 Panacea Holdings, LLC | 390000 0.1114% | $1.83M | 1 | 0 | ||
| FALBERG KATHRYN E | director | 250000 0.0714% | $1.17M | 4 | 0 | <0.0001% |
| BLICKENSTAFF KIM D | director | 172189 0.0492% | $807,566.41 | 1 | 0 | <0.0001% |
| Sjogren Colleen | Chief Commercial Officer | 81000 0.0231% | $379,890.00 | 1 | 0 | +148.92% |
| Bazemore Robert B | director | 5000 0.0014% | $23,450.00 | 1 | 0 | <0.0001% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$607,395,062 | 99 | 4.23% | $1.88B | |
$54,660,406 | 66 | 22.24% | $1.5B | |
$61,893,001 | 38 | 19.63% | $1.89B | |
$530,111,731 | 35 | 8.69% | $1.51B |
| Increased Positions | 127 | +53.81% | 24M | +10.9% |
| Decreased Positions | 104 | -44.07% | 33M | -15.08% |
| New Positions | 57 | New | 11M | New |
| Sold Out Positions | 33 | Sold Out | 10M | Sold Out |
| Total Postitions | 259 | +9.75% | 211M | -4.18% |
| Fmr Llc | $433,895.00 | 14.74% | 50.57M | -468,839 | -0.92% | 2025-09-30 |
| Decheng Capital Llc | $222,689.00 | 7.57% | 25.95M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $211,104.00 | 7.17% | 24.6M | -1M | -4.39% | 2025-09-30 |
| Vanguard Group Inc | $132,600.00 | 4.51% | 15.45M | -448,459 | -2.82% | 2025-09-30 |
| Laurion Capital Management Lp | $83,273.00 | 2.83% | 9.71M | -535,174 | -5.23% | 2025-09-30 |
| Omega Fund Management, Llc | $75,771.00 | 2.58% | 8.83M | -2M | -20.03% | 2025-09-30 |
| State Street Corp | $52,245.00 | 1.78% | 6.09M | +530,201 | +9.54% | 2025-09-30 |
| Geode Capital Management, Llc | $50,517.00 | 1.72% | 5.89M | -107,043 | -1.79% | 2025-09-30 |
| Millennium Management Llc | $41,632.00 | 1.42% | 4.85M | -527,967 | -9.81% | 2025-09-30 |
| Nuveen, Llc | $39,182.00 | 1.33% | 4.57M | +3M | +207.45% | 2025-09-30 |